New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

1 SOURCE CONFIRMED · FIRST SEEN 2026-10-09 11:00 UTC

EXHIBIT · mmx.prnewswire.com

KINDNews

DIRECTION▲ Bullish

SOURCES1

ENTITIES3

STORY SIZESTANDALONE

FIRST SEEN2026-10-09 11:00 UTC

LAST UPDATE2026-10-09 11:00 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Two-year Phase 3 psoriasis data support a potential new drug franchise, strengthening JNJ's immunology pipeline.

Long-term psoriasis data bolster JNJ immunology pipeline

CATALYST TO WATCH

Regulatory filing and approval decisions

MAIN RISK

Competitive immunology market pressures pricing

FULL DISPATCH

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable safety profile SPRING HOUSE, Pa., Oct. 9, 2026 /PRNewswire/ -- Johnson...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDJohnson & Johnson · JNJ

AFFECTEDHealthcare

AFFECTEDSPDR Biotech ETF · XBI

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED

№ 01prnewswireprnewswire.com · PRIMARY2026-10-09 11:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

→CORRELATIONshares Healthcare, XBI
Fidelity-Backed City Therapeutics Seeks $184.7 Million in US IPO2026-10-09 11:15 UTC

→CORRELATIONshares Healthcare, XBI
TRex Bio prices $117M IPO to support immune drug work2026-10-09 11:22 UTC

→CORRELATIONshares Healthcare
Leading Through a Changing Water Management Landscape2026-10-09 11:40 UTC

←CORRELATIONshares Healthcare
SEC-FDA agreement intensifies pharma oversight2026-10-09 04:01 UTC

←CORRELATIONshares Healthcare
TETRAPHARM appoints Rolf Sass Sørensen as Chief Executive Officer2026-10-09 06:56 UTC

←CORRELATIONshares Healthcare
Iambic prices its IPO, seeking to raise up to $160m - pharmaphorum2026-10-09 06:58 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.